Wize Pharma prevalent Real Value cannot be determined due to lack of data. The last-minute price of Wize Pharma is S213.0. Based on Macroaxis valuation methodology, the organization cannot be evaluated at this time. Macroaxis calculates value of Wize Pharma from examining the organization fundamentals such as Current Valuation of 35.93M, EBITDA of
(1.31M) and Shares Outstanding of 22.67M as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we encourage to purchase undervalued securities and to sell overvalued securities since at some point equities prices and their ongoing real values will grow together.
April 19, 2019
Wize Pharma is Unknown risk asset. Calculation of real value of Wize Pharma is based on 2 months time horizon. Increasing Wize Pharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
|Horizon||30 Days Login to change|
Wize Pharma Total Value AnalysisWize Pharma is at this time anticipated to have takeover price of 35.93M with market capitalization of 35.89M, debt of 707K, and cash on hands of 275K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Wize Pharma fundamentals before making investing decisions based on the enterprise value of the company
Wize Pharma Asset UtilizationWize Pharma maintains negative operation of resources of -80.74 (%), securing only S0.81 for each shekel of resources held by the organization. Inadequate assets utilization attests that the company is being less effective with each shekel of resources it maintains. Specifically assets utilization of Wize Pharma shows how discouraging it operates for each shekel spent on its resources.
Wize Pharma Profitability AnalysisThe company reported revenue of . Net Loss for the year was (1.91M).